Managing global regulatory submissions can feel like solving an enormous jigsaw puzzle under strict requirements and against the clock. Each puzzle piece must fit together perfectly. If the result is not compliant, the submission could be delayed or even rejected. Whilst these intricate challenges are not new, risks to success have accelerated over time. Increased competition is generating lightning-fast timelines in addition to heightened accuracy requirements.
Some organisations pass through these complexities with ease; however, many companies face repeated challenges and risks. Fragmented workflows, misaligned teams and rushed processes increase the likelihood of delays and rejection. The risks increase when the business model requires outsourcing of both regulatory affairs and translation responsibilities.
Greater efficiency is possible, and it is achieved through integration. In this article we outline why integration is essential when both regulatory and translation services are outsourced.
Why outsourcing has become a critical strategy
Outsourcing allows pharmaceutical sponsors of all sizes to leverage external expertise and infrastructure in a cost-effective way. It enables flexible scaling of operations, tactical allocation of resources and a more strategic focus on core business priorities. This approach also mitigates the risks associated with fluctuating demand, as sponsors can tap into specialised on-demand support tailored to their changing needs. Sponsors have successfully outsourced many aspects of clinical development for decades. However, if the selected outsourcing model is de-centralised and not closely linked with effective communication, the resulting inefficiencies and fragmented processes can lead to major problems.
Decentralisation risks fragmentation
A typical scenario where lack of regulatory and translation integration cause problems is during a global approval strategy. Imagine your team is preparing to launch regulatory filings in 30+ targeted countries and to manage this the regulatory affairs and language responsibilities are outsourced within a dual partner model: separate vendor partners for regulatory and language services, overseen independently by the sponsor.
Initially, everything is under control. The regulatory team focuses on the dossier’s progress, ensuring authoring and component handoffs are coordinated and aligned, while the language service providers (LSPs) handle the translations requirements. Late in the submission process the regulatory team is notified of a delay in the authoring of a critical and large component set. This forces the team to quickly analyse the landscape, assess its impact, and determine a mitigation strategy. This process is made more challenging because of the existing outsourcing structure. Each LSP works in isolation, requiring multiple rounds of back-and-forth communication as well as tremendous effort to formalise and roll out a mitigation strategy. The sponsor is burdened with managing multiple providers leading to additional delays and mounting costs.
This scenario highlights the common challenges that arise when services are decentralised. When regulatory and translation services operate independently, and under varying and often competing brand names, inefficiencies multiply, miscommunications grow and administrative burdens skyrocket. Without an overarching integrated process, companies risk delays and threats to their global product launches.
How can you better manage these inefficiencies and risks?
When both regulatory affairs and translation responsibilities are handled externally, an integrated regulatory and translation delivery model is key to success. Combining regulatory expertise and language services under the roof of a single partnership transforms the process to achieve:
- Strong collaboration from the start of the submission, leading to better alignment on expectations and timelines
- Real-time management of timelines and priorities, without the need for additional oversight: Integration means no loss of momentum or delays in communication that easily compound when managing large dossiers with tight timelines
- Fewer handoffs: By reducing the number of stakeholders involved, the risk of miscommunication and data inconsistencies decreases and sponsors avoid handoff-related delays
- Concurrent processes: Regulatory submission preparation and localisation (e.g., translation of product information, labels and leaflets) can be done simultaneously, expediting timelines
- Agile operations: Changes and updates are common in the iterative documentation process, and integration ensures regulatory and translation tracks are aligned with adjustments possible in real time
- Audit-ready processes: Integrated service providers can implement standardised, traceable workflows across the board that simplify regulatory audits and inspections
- Easier oversight: Eliminate oversight and management burden with streamlined workflow through a single point of contact. Integrated services deliver through a single source, avoiding the challenge of coordinating between multiple vendors, reducing inefficiencies and time delays
- Centralised specialist expertise: Providers with both regulatory and language capabilities bring expertise in local regulations and cultural nuances, ensuring compliance in diverse markets.
The benefits of an integrated delivery model
One of the key advantages of an integrated delivery model is the ability to use resources that work within the same ecosystem. When regulatory affairs and translation experts collaborate within the same organisation, it fosters trust, flexibility, and efficiency that enable:
Open communication
With all teams working within the same organisation, the communication loop is open. Sensitive information, product strategies and updates can be discussed openly without concerns about confidentiality or competition. Handoffs that slow down traditional set ups are minimised.
Seamless collaboration
Regulatory and translation teams have access to the same systems, processes and tools, ensuring alignment at every stage of the submission process. They operate from a unified understanding of objectives, priorities and deadlines, effectively removing the barriers that typically hinder traditional setups.
Proactive problem solving
Having regulatory and translation services delivered from the same organisation allows the team to proactively monitor and anticipate issues before they arise. If a dossier component is delayed, the regulatory team informs the translation team through designated contacts, allowing for immediate risk mitigation and problem-solving.
Shared knowledge base
Teams within the same company benefit from a collective and robust knowledge base. This includes sharing regulatory expertise, language nuances and cultural considerations. This knowledge-sharing ensures translations are accurate and fully aligned with the regulatory strategy.
Lowered administrative burden
Clients are no longer burdened with managing multiple vendors or facilitating communications between separate entities. The integrated team takes care of everything, delivering a streamlined end-to-end service.
A trusted partner from molecule to medicine
Managing a global submission does not have to be an uphill battle. By adopting ICON’s integrated regulatory and translation delivery model, companies can eliminate risks, ensure compliance, and accelerate their time to market. ICON’s integrated delivery model allows regulatory affairs and language services to be integrated and seamlessly delivered throughout the submission process, so all goals are achieved. Our experts’ industry knowledge, global experience and operational excellence positions us to help you achieve market success.
Powered by the healthcare intelligence of its teams, ICON’s end-to-end service offerings include regulatory experts dedicated to guiding global submissions from start to finish. Our Regulatory Affairs team has strong knowledge of complex international regulations and more than 35 years of experience managing submissions across multiple therapeutic areas.
ICON Language Services is the industry’s largest life sciences language services provider. Our 2,700+ experts cover more than 300 languages, specialising in life science translations including regulatory clinical and commercial documentation. The team understands the critical nuances of translating life sciences content, ensuring submissions meet country-specific regulatory language requirements while safeguarding accuracy and compliance.
Contact us to learn how we can integrate your regulatory submissions and translation requirements.
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Decoding AI in software as a medical device (SaMD)
-
Software as a medical device (SaMD)
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Challenges and opportunities in Parkinson’s Disease clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
Key Considerations in Chronic Pain Clinical Trials
-
ICON survey report: CNS therapeutic development
-
A mind for digital therapeutics
-
Glycomics
- Infectious Diseases
- NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel